Cogent Biosciences (COGT) News Today

Needham & Company LLC reaffirmed a "buy" rating and set a $18.00 price objective on shares of Cogent Biosciences in a research report on Monday.

HC Wainwright reissued a "buy" rating and issued a $19.00 target price on shares of Cogent Biosciences in a research report on Monday.

Perceptive Advisors LLC cut its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 51.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,122,958 shares of the technology compan

Frazier Life Sciences Management L.P. lifted its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 32.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,995,267 shares of the technology company's stock a

Rafferty Asset Management LLC grew its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 50.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 288,671 shares of the technology company's stock after acq

Kynam Capital Management LP grew its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 164.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,854,766 shares of the technology company's stock after

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.4%

New Leaf Venture Partners L.L.C. reduced its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 250,765 shares of the technology company's

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 13,460,000 shares, an increase of 11.8% from the April 30th total of 12,040,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is presently 8.7 days.

Cogent Biosciences (NASDAQ:COGT) Stock Price Up 5.5%

Cogent Biosciences (NASDAQ:COGT) Shares Down 6.1%

Wedbush reissued a "neutral" rating and issued a $10.00 price objective on shares of Cogent Biosciences in a research report on Friday.

Cogent Biosciences (NASDAQ:COGT) Trading Down 6.4%

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a note issued to investors on Monday, May 13th. HC Wainwright analyst R. Burns now anticipates that the technology company

HC Wainwright reissued a "buy" rating and set a $19.00 price target on shares of Cogent Biosciences in a research report on Monday.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2024 earnings estimates for Cogent Biosciences in a report issued on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now forecasts that the technology company will post earnings per

Needham & Company LLC restated a "buy" rating and set a $18.00 price objective on shares of Cogent Biosciences in a research note on Wednesday.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) released its quarterly earnings data on Tuesday. The technology company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11).

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 12,470,000 shares, a growth of 15.0% from the March 31st total of 10,840,000 shares. Based on an average trading volume of 2,100,000 shares, the short-interest ratio is presently 5.9 days.

Cogent Biosciences (NASDAQ:COGT) Trading 11.5% Higher

Cogent Biosciences (NASDAQ:COGT) Trading Down 8.3%

Cogent Biosciences (NASDAQ:COGT) Trading Up 4%

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The av

Cogent Biosciences (NASDAQ:COGT) Trading Down 7.3%

Cogent Biosciences (NASDAQ:COGT) Shares Up 6.3%

Cogent Biosciences (NASDAQ:COGT) Shares Down 8%

SG Americas Securities LLC grew its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 203.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 317,409 shares of the technology company's stock

Cogent Biosciences (NASDAQ:COGT) Shares Up 10.4%

Cogent Biosciences (NASDAQ:COGT) Stock Price Down 5.2%

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have

Cogent Biosciences (NASDAQ:COGT) Shares Gap Down to $7.05

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 9,070,000 shares, an increase of 45.4% from the February 14th total of 6,240,000 shares. Based on an average daily volume of 2,600,000 shares, the short-interest ratio is presently 3.5 days.

Cogent Biosciences (NASDAQ:COGT) Trading 2.4% Higher

Cogent Biosciences (NASDAQ:COGT) Shares Down 4%

Kynam Capital Management LP boosted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 36.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,210,125 shares of the technology

Fmr LLC grew its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 1,322.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,569,781 shares of the technology company's stock after purchas